Go for the GOLD: 2021 Chronic Obstructive Pulmonary Disease (COPD) Updates

A presentation for HealthTrust Members February 23, 2022



CHELSEA SUPPINGER, PHARMD, PGY1 PHARMACY RESIDENT MEMORIAL HOSPITAL OF SOUTH BEND KAITLYN DEWEERD, PHARMD, BCPS, PRECEPTOR

Speaker Disclosures

- The presenter and their preceptor have no financial relationships with any commercial interests pertinent to this presentation.
- This program may contain the mention of drugs, brands or suppliers presented in a case study or comparative format using evidencebased research. Such examples are intended for educational and informational purposes and should not be perceived as an endorsement of any particular drug, brand or supplier.

Objectives

Recall guideline updates to recommendations and current trends in COPD treatment

1.

3.

2.

Identify recently published outcomes and studies regarding COPD management

Recognize appropriate recommendations for pharmacologic therapy in COPD patients based on new clinical evidence

Definitions

Diagnosis, Spirometry, Assessment COPD: Chronic Obstructive Pulmonary Disease FVC: forced vital capacity FEV1: forced expiratory volume in 1 second mMRC: Modified Medical Research Council CAT: COPD Assessment Test

<u>Treatment</u> LABA: long-acting beta agonist LAMA: long-acting muscarinic antagonist ICS: inhaled corticosteroid

<u>Other</u>

Eos: eosinophils cAMP: cyclic adenosine monophosphate ATP: adenosine triphosphate RCT: randomized controlled trial

Overview

5

Background

Prevention Updates

Treatment Updates

COPD during COVID19

Knowledge Check 1

Which of the following was NOT a finding of a recently published study on COPD treatments?

- A. E-cigarettes were found to be a safe and effective method to help patients quit smoking
- B. LABA/LAMA improved symptoms compared to long acting bronchodilator monotherapy in patients with low exacerbation risk not on ICS
- C. LABA/LAMA/ICS therapy reduced risk of death in symptomatic patients at risk for exacerbation compared to LABA/LAMA or ICS/LABA
- D. Lower-dose inhaled glucocorticoid tripletherapy regimen showed greater efficacy than higher dose glucocorticoid-LABA regimen, with greater reductions in symptoms

Knowledge Check 1-Correct Response

Which of the following was NOT a finding of a recently published study on COPD treatments?

- A. E-cigarettes were found to be a safe and effective method to help patients quit smoking
- B. LABA/LAMA improved symptoms compared to long acting bronchodilator monotherapy in patients with low exacerbation risk not on ICS
- C. LABA/LAMA/ICS therapy reduced risk of death in symptomatic patients at risk for exacerbation compared to LABA/LAMA or ICS/LABA
- D. Lower-dose inhaled glucocorticoid tripletherapy regimen showed greater efficacy than higher dose glucocorticoid-LABA regimen, with greater reductions in symptoms


Background

What is COPD?

COPD is common, preventable and treatable

- COPD is characterized by:
 - Persistent respiratory symptoms
 - Airway and/or alveolar abnormalities





Death rates (per 100,000 US population) were age-adjusted to the 2000 US standard population.

Date: 3/30/2921

10

Risk Factors









Age and sex



Indoor air pollution



Lung growth and development/asthma



Occupational exposures




Infections/chronic bronchitis




Outdoor air

pollution

Genetic factors





13

Image available at: https://www.nhlbi.nih.gov/health-topics/copd#Signs,-Symptoms,-and-Complications

Diagnosis


COPD is NOT a clinical diagnosis

Spirometry required to confirm diagnosis

SYMPTOMS

- Shortness of Breath
- Chronic Cough
- Sputum






14

Assessment Scales

Moderate or Severe Exacerbation History

≥2 or \geq 1 leading to hospital admission 0 or 1 (not leading to hospital admission)



Source: Vogelmeier C, Agusti A, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2021 report

Symptoms

Assessment Scales

MODIFIED MRC DYSPNEA SCALE^a

PLEASE TICK IN THE BOX THAT APPLIES TO YOU | ONE BOX ONLY | Grades 0 - 4

mMRC Grade 0.	I only get breathless with strenuous exercise.		
mMRC Grade 1.	I get short of breath when hurrying on the level or walking up a slight hill.		
mMRC Grade 2.	I walk slower than people of the same age on the level because of breathlessness, or I have to stop for breath when walking on my own pace on the level.		
mMRC Grade 3.	I stop for breath after walking about 100 meters or after a few minutes on the level.		
mMRC Grade 4.	I am too breathless to leave the house or I am breathless when dressing or undressing.		
^a Fletcher CM. BMJ 1960; 2: 1662.			

Assessment Scales

Cutoff at 10

CAT[™] ASSESSMENT

For each item below, place a mark (x) in the box that best describes you currently. Be sure to only select one response for each question.

EXAMPLE: I am very happy	0 2 3 4 5	I am very sad	SCORE
I never cough	012345	I cough all the time	
l have no phlegm (mucus) in my chest at all	012345	My chest is completely full of phlegm (mucus)	
My chest does not feel tight at all	012345	My chest feels very tight	
When I walk up a hill or one flight of stairs I am not breathless	012345	When I walk up a hill or one flight of stairs I am very breathless	
I am not limited doing any activities at home	012345	I am very limited doing activities at home	
I am confident leaving my home despite my lung condition	012345	I am not at all confident leaving my home because of my lung condition	
I sleep soundly	012345	I don't sleep soundly because of my lung condition	
I have lots of energy	012345	I have no energy at all	
Reference: Jones et al. ERJ 2009; 3	4 (3); 648-54.	TOTAL SCORE	

Treatment and Updates



18

19

Vaccination for Stable COPD

Influenza

• Reduces serious illness and death in COPD patients

Pneumovax 23® (PPSV23)

• COPD patients < 65 yo with FEV₁ < 40% predicted and those with comorbidities to reduce community acquired pneumonia

Prevnar 13® (PCV13)

• COPD patients greater than or equal to 65 to reduce bacteremia and pneumococcal disease

Tetanus, Diphtheria, Pertussis (Tdap)

• COPD patients who were not vaccinated in adolescence to protect against pertussis (whooping cough)

Knowledge Check 2

E-cigarettes contain all of the following ingredients EXCEPT:

- A. Nicotine
- B. Reactive oxygen species
- C. Volatile carbonyls
- D. All of the above can be contained in ecigarettes
- E. Only A and B


21

Knowledge Check 2 – Correct Response

E-cigarettes contain all of the following ingredients EXCEPT:

- A. Nicotine
- B. Reactive oxygen species
- C. Volatile carbonyls
- D. All of the above can be contained in ecigarettes
- E. Only A and B

Smoking Cessation



22

Smoking Cessation 🗡

- E-cigarettes and vaping
 - Contain nicotine, propylene glycol, volatile carbonyls, diacetyl, reactive oxygen species, furones, and metals

23

- Case reports of severe acute lung injury, eosinophilic pneumonia, alveolar hemorrhage, respiratory bronchitis, and sometimes death
- E-cigarette or vaping associated lung injury (EVALI) outbreak was investigated by FDA and CDC
 - Vitamin E acetate was found to be linked to EVALI and cases have decreased since
 - Airway inflammation and irritability, ciliary paresis, and mucus hypersecretion seen in animal and in vitro human models

Initial Management

≥ 2 moderate exacerbations or ≥ 1 leading to hospitalization	Group C LAMA	Group D LAMA or LAMA + LABA* or ICS + LABA** *Consider if highly symptomatic (e.g. CAT > 20) **Consider if eos ≥ 300
0 or 1 moderate exacerbations (not leading to hospital admission)	Group A A Bronchodilator	Group B A Long Acting Bronchodilator (LABA or LAMA)
	mMRC 0-1, CAT < 10	mMRC \geq 2, CAT \geq 10

24

Bronchodilator Therapy


- Increase FEV₁ and/or change other spirometric variables
- Most often given on a regular basis to prevent or reduce symptoms



25

Beta2 Agonists

- Primary action is to relax airway smooth muscle
- Adverse effects:
 - Nervousness
 - Tachycardia
 - Cough
 - Hyperglycemia
 - Decreased potassium



Source: Vogelmeier C, Agusti A, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2021 report


β2-agonists do not work in children under 2 years of age: myth or maxim? | European Respiratory Society (ersjournals.com)

Short-Acting B ₂ Agonists (SABA)			
Medication	Inhaler Type	Nebulizer Solution Available?	Duration of Action
Levalbuterol (Xopenex®)	Metered dose inhaler (MDI)	Yes	6-8 hours
Albuterol (ProAir®, Ventolin®, Proventil®)	Metered dose inhaler (MDI) Dry powder inhaler (DPI)	Yes	4-6 hours
Long-Acting B ₂ Agonists (LABA)			
Medication	Inhaler Type	Nebulizer Solution Available?	Duration of Action
Formoterol (Foradil®)	Dry powder inhaler (DPI)	Yes	12 hours
Indacaterol (Arcapta®)	Dry powder inhaler (DPI)	No	12 hours
Olodaterol (Striverdi Respimat®)	Soft mist inhaler (SMI)	No	24 hours
Salmeterol (Serevent®)	Metered dose inhaler (MDI) Dry powder inhaler (DPI)	No	12 hours

27

Muscarinic Antagonists

- Block bronchoconstrictor effects of acetylcholine at M3 muscarinic receptors expressed in airway smooth muscle
- Adverse effects:
 - Dry mouth
 - Bitter taste
 - Upper respiratory tract infections



Source: Vogelmeier C, Agusti A, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2021 report

Long-acting maintenance pharmacotherapy in chronic obstructive pulmonary disease. | Respiratory Medicine: X. (sciencedirect.com)

Short-Acting Muscarinic Antagonists (SAMA)				
Medication	Inhaler Type	Nebulizer Solution Available?	Duration of Action	29
Ipratropium bromide (Atrovent®)	Metered dose inhaler (MDI)	Yes	6-8 hours	

Long-Acting Muscarinic Antagonists (LAMA)			
Medication	Inhaler Type	Nebulizer Solution Available?	Duration of Action
Aclidinium bromide (Tudorza Pressair®)	Metered dose inhaler (MDI), Dry powder inhaler (DPI)	No	12 hours
Tiotropium (Spiriva Handihaler®, Spiriva Respimat®)	Metered dose inhaler (MDI) Dry powder inhaler (DPI) Soft mist inhaler (SMI)	No	24 hours
Umeclidinium (Incruse Ellipta®)	Dry powder inhaler (DPI)	No	24 hours
Glycopyrronium bromide (Seebri Breezhaler®)	Dry powder inhaler (DPI)	Yes	12 hours





Randomized patients at low risk for exacerbation to receive umeclidinium/vilanterol, uneclidinium monotherapy, or salmeterol monotherapy

Results: change from baseline of FEV1 at week 24

LABA/LAMA versus LAMA monotherapy: 66 mL greater (p < 0.001) LABA/LAMA versus LABA monotherapy: 141 mL greater (p < 0.001)

Conclusion: LABA/LAMA combination inhaler improved lung function and symptoms versus long-acting bronchodilator monotherapy in symptomatic patients with low exacerbation risk not receiving inhaled corticosteroids

Source: Maltais F, Bjermer L, Kerwin EM, et al. the EMAX randomised trial. Respir Res 2019; 20(1): 238

31

Combination Bronchodilator Inhalers

SABA/SAMA Inhalers

 Albuterol/ipratropium (Combivent Respimat®, DuoNeb®)

LABA/LAMA Inhalers

- Formoterol/aclidinium (Duaklir Pressair®)
- Formoterol/glycopyrronium (Bevespi Aerosphere®)
- Vilanterol/umeclidinium (Anoro Ellipta®)
- Olodaterol/tiotropium (Stiolto Respimat®)

Methylxanthines

Not recommended unless other bronchodilators not an option

 Contradictory evidence with lowdose therapy

Dose-related toxicity

• Small therapeutic range

Nausea, repetitive vomiting

Adverse Effects


- Arrhythmias
- Grand mal seizures
- Headaches
- Insomnia

Significant interactions with commonly prescribed medications

32

Inhaled Corticosteroids (ICS)

Reduce lung inflammation by inhibiting synthesis of pro-inflammatory mediators



33

Source: Inhaled Corticosteroids Safety and Adverse Effects in Patients with Asthma - The Journal of Allergy and Clinical Immunology: In Practice (jaci-inpractice.org)

Combination ICS Inhalers

LABA/ICS Inhalers

34

- Fluticasone furoate/vilanterol (Breo Ellipta®)
- Fluticasone propionate/salmeterol (Advair®)
- Mometasone furoate/formoterol (Dulera®)
- Budesonide/formoterol (Symbicort®)

ICS Takeaways and Updates

ICS/LABA combination more effective than individual components in improving lung function and reducing exacerbations

35


- Regular treatment with ICS increases pneumonia risk, especially in those with severe disease
- Both current and former smokers benefit from ICS use
 - Magnitude of effect is lower in heavy or current smokers

Studies investigating ICS treatment and risk of lung cancer had conflicting results

Favoring Use

Blood eosinophils >300 cells/microL 2 or more moderate COPD exacerbations per year History of asthma Blood eosinophils <100 cells/microL History of mycobacterial infection Repeated pneumonia events

Against Use



37

Source: Vogelmeier C, Agusti A, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2021 report

Knowledge Check 3

Which patient is the best candidate for triple therapy inhaler based on GOLD guideline recommendations?

- A. Patient on LABA/LAMA inhaler with eosinophils >100 cells/microL, who continues to experience dyspnea and exasperations
- B. Patient on LAMA inhaler, who continues to have dyspnea
- C. Patient on LABA/ICS inhaler, who continues to have exacerbations
- D. Patient on LABA/LAMA inhaler with eosinophils <100 cells/microL, who continues to have dyspnea and exacerbations
- E. A and C

Knowledge Check 3 – Correct Response

Which patient is the best candidate for triple therapy inhaler based on GOLD guideline recommendations?

- A. Patient on LABA/LAMA inhaler with eosinophils >100 cells/microL, who continues to experience dyspnea and exasperations
- B. Patient on LAMA inhaler, who continues to have dyspnea
- c. Patient on LABA/ICS inhaler, who continues to have exacerbations
- D. Patient on LABA/LAMA inhaler with eosinophils <100 cells/microL, who continues to have dyspnea and exacerbations

E. A and C

Triple Therapy Inhaler (LABA/LAMA/ICS)


Improves lung function, patient reported outcomes, and reduces exacerbations New evidence on mortality reduction 40

Source: Vogelmeier C, Agusti A, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2021 report

ORIGINAL ARTICLE

Reduction in All-Cause Mortality with Fluticasone Furoate/Umeclidinium/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease

FF: fluticasone furoate UMEC: umeclidinium VI: vilanterol



Source: Lipson DA, Crim C, Criner GJ, et al. IMPACT, Am J Respir Crit Care Med 2020; 201(12): 1508-16.

IMPACT Results



Conclusion: once-daily FF/UMEC/VI inhaler reduced all-cause mortality versus UMEC/VI in patients with symptomatic COPD and a history of exacerbations

> FF: fluticasone furoate UMEC: umeclidinium VI: vilanterol

42

Source: Lipson DA, Crim C, Criner GJ, et al. IMPACT, Am J Respir Crit Care Med 2020; 201(12): 1508-16.

ORIGINAL ARTICLE

Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD



43

ETHOS Study

Intervention: randomized 1:1:1 to receive BD/GP/FM, BD/FM, or GP/FM

Patient population: 8,509 symptomatic COPD patients (CAT \ge 10) on at least 2 maintenance therapies, postbronchodilator FEV₁ 25% - 65%, smoking history of at least 10 pack years, and either

- 1. \geq 1 moderate or severe exacerbation if FEV₁ <50% OR
- 2. \geq 2 moderate, or 1 severe, exacerbation if FEV₁ \geq 50%

Source: Rabe KF, Martinez FJ, Ferguson GT, et ETHOS. N Engl J Med 2020; 383(1): 35-48.

ETHOS Results

LABA/ICS -

LABA/LAMA

Triple therapy (320mcg):

Triple therapy (160mcg):

• Exacerbation Rate= 1.24 (2131 patients)

44

• Exacerbation Rate= 1.42 (2120 patients)

Exacerbation Rate= 1.08 (2137 patients)
13% lower rate than LABA/ICS (P=0.003)
24% lower rate than LABA/LAMA (P<0.001)

• rate = 1.07 (2121 pts)

- 14% lower rate than LABA/ICS (P=0.002)
- 25% lower rate than LABA/LAMA (P<0.001)

Ethos Conclusion

Triple therapy with twice-daily glycopyrronnium bromide, budesonide, and formoterol resulted in a lower rate of moderate or severe COPD exacerbations than budesonide/fomoterol or glycopyrronnium bromide/formoterol therapy

New Evidence on other Pharmacologic Therapy \cdot

- Erdosteine may have significant effect on mild exacerbations
- RCT looking at metoprolol in COPD patients without established indication for beta-blocker use showed it did not delay the time until first exacerbation, and hospitalization for exacerbation was more common in metoprolol group

46

- Pharmacist-led interventions and lay health coaching can improve inhalation technique and adherence in COPD patients
- Procalcitonin-guided antibiotic treatment regimens have been studied for management of COPD exacerbation with controversial results

Source: Vogelmeier C, Agusti A, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2021 report

COPD and COVID-19



Unknown if COPD increases risk of COVID-19 infection

- One population survey with random sampling found no increased risk of COVID-19 infection
- Most studies of people in the community tested for SARS-CoV-2 have not shown COPD as an independent risk factor

48


- Many studies reporting comorbidities of patients hospitalized with COVID-19 have shown lower COPD prevalence than expected
- A large study with comprehensive data on comorbidities showed a high prevalence of COPD among those admitted (19%)
- A further study showed COPD as an independent risk factor for hospital admission

Takeaway: increased risk of hospitalization and severe disease

Source: Vogelmeier C, Agusti A, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2021 report

When to Get Tested

- Patients with COPD presenting with
 - Respiratory symptoms
 - Fever
 - Other symptoms suggestive of COVID-19 infection



49

Source: Vogelmeier C, Agusti A, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2021 report

Available at: https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html

Protective Strategies



Follow basic infection control measures



Wear a face covering

Consider shielding/sheltering in place


COVID-19 vaccination/annual influenza vaccination 50




Only essential spirometry

Source: Vogelmeier C, Agusti A, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2021 report

ICS Therapy during COVID-19 Pandemic



Other Pharmacologic Treatment during COVID-19 Pandemic



Source: Vogelmeier C, Agusti A, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2021 report

Treatment of COPD Exacerbations during COVID-19 Pandemic

Coronaviruses are among the respiratory viruses that trigger COPD exacerbations

To date MERS-CoV, SARS-CoV, and SARS-CoV-2 infections have not been reported in COPD exacerbations

Continue recommended treatments according to usual indications

Systemic corticosteroids

Antibiotics

53

Source: Vogelmeier C, Agusti A, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2021 report

Treatment of COVID-19 Infection in COPD Patients

54

No recommendations to change management of COVID-19 in COPD patients

> Continue usual course of therapy as indicated by patient parameters

Source: Vogelmeier C, Agusti A, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2021 report

Knowledge Check 4

What is the most appropriate recommendation based on the patient case?

LB is a 64 year old male with COPD currently on salmeterol/fluticasone (Advair Diskus®) inhaler. LB has persistent dyspnea despite his current regimen but has not had any exacerbations since starting treatment. He had a case of pneumonia less than a year ago. His labs show a blood eosinophil count of 67 cells/microL.

- A. Recommend starting LB on fluticasone furoate/umeclidinium/vilanterol (Trelegy Ellipta®)
- B. Recommend switching LB to formoterol/budesonide (Symbicort®)
- C. Recommend switching LB to vilanterol/umeclidinium (Anoro Ellipta®)
- D. Recommend adding roflumilast (Daliresp®)

Knowledge Check 4 – Correct Response

What is the most appropriate recommendation based on the patient case?

LB is a 64 yo male with COPD currently on salmeterol/fluticasone (Advair Diskus®). LB has persistent dyspnea despite his current regimen but has not had any exacerbations since starting treatment. He had a case of pneumonia less than a year ago. His labs show an eosinophil count of 67.

56

A. Recommend starting LB on fluticasone furoate/umeclidinium/vilanterol (Trelegy Ellipta®)

B. Recommend switching from LB to formoterol/budesonide (Symbicort®)

C. Recommend switching LB to vilanterol/ umeclidinium (Anoro Ellipta®)

D. Recommend adding roflumilast (Daliresp®)

Summary

New evidence has been added on

E-cigarettes and vaping

LABA/LAMA combination therapy versus bronchodilator monotherapy

Inhaled corticosteroid use in current or heavy smokers and in lung cancer

57

Triple therapy benefits

COPD treatment in context of COVID-19 pandemic

References

Lipson DA, Crim C, Criner GJ, et al. Reduction in All-Cause Mortality with Fluticasone Furoate/Umeclidinium/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med 2020; 201(12): 1508-16.

- Maltais F, Bjermer L, Kerwin EM, et al. Efficacy of umeclidinium/vilanterol versus umeclidinium and salmeterol monotherapies in symptomatic patients with COPD not receiving inhaled corticosteroids: the EMAX randomised trial. Respir Res 2019; 20(1): 238
- Rabe KF, Martinez FJ, Ferguson GT, et al. Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderateto-Very-Severe COPD. N Engl J Med 2020; 383(1): 35-48.
- Sonnex K, Alleemudder H, Knaggs R. Impact of smoking status on the efficacy of inhaled corticosteroids in chronic obstructive pulmonary disease: a systematic review. BMJ Open 2020; 10(4): e037509.
- Vogelmeier C, Agusti A, Anzueto A, et al. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2021 report
- Vogelmeier C, Agusti A, Anzueto A, et al. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2022 report

59

Thank you!

Chelsea Suppinger, PharmD, PGY1 Pharmacy Resident Memorial hospital of South Bend csuppinger@beaconhealthsystem.org